Table of Contents
The UF Diabetes Institute serves as the umbrella organization that coordinates research, treatment, and education at UF and UF Health, the university's academic health center.
Researchers and physicians at the University of Florida Diabetes Institute work in a wide range of fields, including immunology and genetics, to prevent, diagnose, and treat diabetes. UF is an international research leader in the treatment and management of type 1 diabetes.
make a reservation
For new patientsyou will need a referral letter from your family doctor to our hospital. For more information, please call our main number (352) 265-8228 or email [email protected].
Telemedicine appointment
Children with diabetes who live hours away from Gainesville can now receive specialized care closer to home thanks to a telemedicine program. The program connects health care providers and patients through the Internet and telehealth technology to improve care. Telehealth appointments are conducted via a HIPAA-compliant version of Zoom, a video conferencing platform suitable for medical use.
- Please call us if you would like to make a reservation (352) 265-3422.
- Before making your appointment, please visit UF Health Telehealth to learn how to access your appointment.
- Please contact the clinic in advance to learn how to upload data from your diabetes device (meter, insulin pump, continuous glucose monitor). Your diabetes doctor needs this information to give you a meaningful consultation. Please plan to upload your data by the night before your visit.
Clinical Trial: Diabetes
UF Health's research scientists improve medicines every day. They discover new ways to help people by conducting clinical trials. By participating in a clinical trial, you can receive advanced medical care. In some cases, it may take years before it is available anywhere. You can also help make health care better for others. If you would like to learn more about clinical trials, please visit our clinical trials page. Or click one of the links below.
Lactobacillus johnsonii N6.2 in children and adolescents with T1D
Genetics has been shown to be a major risk factor for the development of type 1 diabetes (T1D), while microbiota imbalance has been suggested to be a trigger for immune tolerance and beta-cell autoimmunity. Probiotic Lactobacillus johnsonii N6.2…
- investigator
- Michael J. Haller
- situation
- Candidate acceptance
- age
- 8 to 18 years old
- sex
- all
L. johnsonii in adults with T1D
Genetics has been shown to be a major risk factor for the development of type 1 diabetes (T1D), while microbiota imbalance has been suggested to be a trigger for immune tolerance and beta-cell autoimmunity. Probiotic Lactobacillus johnsonii N6.2…
- investigator
- Michael J. Haller
- situation
- Candidate acceptance
- age
- 18 to 45 years old
- sex
- all
ITN095AI designation
This is a multicenter, Phase Ib, open-label, ciplizumab dose-finding study in individuals aged 8 to 45 years diagnosed with type 1 diabetes mellitus (T1DM). Within 18 months of V0. Participants are randomly assigned to one of four candidates in a 1:1:1:1 ratio.
- investigator
- Desmond Schatz
- situation
- Candidate acceptance
- age
- 8 years to 45 years
- sex
- all
See all diabetes studies
